{"nctId":"NCT00141453","briefTitle":"ORIENT: Olmesartan Reducing Incidence of End Stage Renal Disease in Diabetic Nephropathy Trial","startDateStruct":{"date":"2003-04"},"conditions":["Diabetic Nephropathy","Type 2 Diabetes Mellitus","Proteinuria"],"count":577,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: olmesartan medoxomil"]},{"label":"2","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo Tablets"]}],"interventions":[{"name":"olmesartan medoxomil","otherNames":[]},{"name":"Placebo Tablets","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* clinical diagnosis of diabetic nephropathy in patients with type 2 diabetes\n* albumin-to-creatinine ratio \\>= 300 mg/g creatinine in first morning urinalysis\n* serum creatinine between 1.0 and 2.5 mg/dL in women and between 1.2 and 2.5 mg/dL in men\n\nExclusion Criteria:\n\n* type 1 diabetes\n* non-diabetic nephropathy\n* history of myocardial infarction\n* history of cardiac bypass grafting within 3 months\n* history of percutaneous coronary intervention (PCI) within 6 months\n* history of carotid artery or peripheral artery revascularization within 6 months\n* stroke or transient ischemic attack (TIA) within 1 year\n* unstable angina pectoris\n* heart failure of NYHA functional classes III or IV\n* rapid progression of kidney disease within 3 months\n* severe orthostatic hypotension\n* serum potassium level =\\<3.5 mEq(mmol)/L or =\\>5.5 mEq(mmol)L\n* history of rapid elevation of the serum creatinine level after starting treatment with AII receptor antagonists or ACE inhibitors\n* poor glycemic control: HbA1c level =\\>11%\n* history of myocardial infarction (MI) or coronary artery bypass grafting (CABG) within 3 months","healthyVolunteers":false,"sex":"ALL","minimumAge":"30 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Renal Composite Outcomes","description":"first occurrence of any of the following events: Doubling of serum creatinine level; Death; End stage renal disease","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"116","spread":null},{"groupId":"OG001","value":"129","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Experiencing Cardiovascular Composite Outcomes","description":"Number of participants experiencing the first occurence of any of the following: Cardiovascular death; non-fatal stroke; non-fatal myocardial infarction; hospitalization for unstable angina; lower extremity amputation; coronary/carotid/peripheral revascularization.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null},{"groupId":"OG001","value":"53","spread":null}]}]}]},{"type":"SECONDARY","title":"The Change in Proteinuria","description":"The median percentage change from baseline value in urinary protein:creatinine ratio","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-19.5","spread":null},{"groupId":"OG001","value":"12.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-20.0","spread":null},{"groupId":"OG001","value":"6.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-24.9","spread":null},{"groupId":"OG001","value":"3.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Reciprocal (1/Serum Creatinine) of Serum Creatinine","description":"The amount of serum creatinine was determined by blood tests periodically during the study. The amount of creatinine is an indication of kidney function. The reciprocal of serum creatinine is used in an equation to determine the change in kidney function from baseline. The reciprocal of the serum creatinine was monitored to detect kidney function changes over duration of the study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.071","spread":null},{"groupId":"OG001","value":"-0.089","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":147,"n":287},"commonTop":["Nasopharyngitis","Oedema peripheral","Hypoglycaemia","Hyperkalaemia","Cough"]}}}